Your browser doesn't support javascript.
loading
Orthobiologic Management Options for Degenerative Disc Disease.
de Oliveira, Cezar Augusto Alves; Oliveira, Bernardo Scaldini; Theodoro, Rafael; Wang, Joshua; Santos, Gabriel Silva; Rodrigues, Bruno Lima; Rodrigues, Izair Jefthé; Jorge, Daniel de Moraes Ferreira; Jeyaraman, Madhan; Everts, Peter Albert; Navani, Annu; Lana, José Fábio.
Afiliação
  • de Oliveira CAA; Orthopedics, ABCOliveira Medical Clinic, São Paulo 03310-000, SP, Brazil.
  • Oliveira BS; Orthopedics, ABCOliveira Medical Clinic, São Paulo 03310-000, SP, Brazil.
  • Theodoro R; Orthopedics, ABCOliveira Medical Clinic, São Paulo 03310-000, SP, Brazil.
  • Wang J; Learning and Teaching Unit, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • Santos GS; Department of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
  • Rodrigues BL; Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
  • Rodrigues IJ; Department of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
  • Jorge DMF; Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
  • Jeyaraman M; Department of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
  • Everts PA; Department of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
  • Navani A; Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
  • Lana JF; Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
Bioengineering (Basel) ; 11(6)2024 Jun 10.
Article em En | MEDLINE | ID: mdl-38927827
ABSTRACT
Degenerative disc disease (DDD) is a pervasive condition that limits quality of life and burdens economies worldwide. Conventional pharmacological treatments primarily aimed at slowing the progression of degeneration have demonstrated limited long-term efficacy and often do not address the underlying causes of the disease. On the other hand, orthobiologics are regenerative agents derived from the patient's own tissue and represent a promising emerging therapy for degenerative disc disease. This review comprehensively outlines the pathophysiology of DDD, highlighting the inadequacies of existing pharmacological therapies and detailing the potential of orthobiologic approaches. It explores advanced tools such as platelet-rich plasma and mesenchymal stem cells, providing a historical overview of their development within regenerative medicine, from foundational in vitro studies to preclinical animal models. Moreover, the manuscript delves into clinical trials that assess the effectiveness of these therapies in managing DDD. While the current clinical evidence is promising, it remains insufficient for routine clinical adoption due to limitations in study designs. The review emphasizes the need for further research to optimize these therapies for consistent and effective clinical outcomes, potentially revolutionizing the management of DDD and offering renewed hope for patients.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Bioengineering (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Bioengineering (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça